Department of Respiration Medicine, Shanghai General Hospital of Nanjing Medical University, Shanghai, China.
Department of Respiratory, Shanghai General Hospital, Shanghai Jiao Tong University, Shanghai, China.
Kaohsiung J Med Sci. 2020 Feb;36(2):107-113. doi: 10.1002/kjm2.12147. Epub 2019 Nov 29.
Increasing evidence has indicated the intimate relationship between the gastrointestinal tract and respiratory tract. The microbial ecosystem has been confirmed to share key conceptual features with gut-lung microbiome disorder and dysregulation during chronic obstructive pulmonary disease (COPD) exacerbations. However, the dynamic changes of the gut-lung microbiome during COPD exacerbations and its potential role in disease etiology remain poorly understood. The present study investigated the dynamic changes of gut and lung microorganisms during acute exacerbation of chronic obstructive pulmonary disease (AECOPD). A longitudinal 16S ribosomal DNA survey of the gut and lung microbiome was completed on 90 feces and sputum samples collected from 15 subjects with AECOPD at three visits, which were defined as exacerbation, seven-day stable state. The present analysis revealed a dynamic gut-lung microbiota, where changes appeared to be associated with exacerbation events indicative of specific exacerbation phenotypes. Antibiotic and steroid treatments appeared to have differential effects on the gut-lung microbiome, and the microbiome was associated with disease progression, but not with severity. The abundance and diversity of the microbiome was strongly influenced by the disease progression and therapy. Using culture-independent methods to impact the gut and lung microbiota on AECOPD may be the key to understanding the interactions between the gut and lung, highlighting its potential as a biomarker, and possibly a target for future respiratory therapeutics.
越来越多的证据表明胃肠道和呼吸道之间存在密切关系。微生物生态系统已被证实与慢性阻塞性肺疾病(COPD)恶化期间的肠道-肺部微生物组紊乱和失调具有关键的概念特征。然而,COPD 恶化期间肠道-肺部微生物组的动态变化及其在疾病发病机制中的潜在作用仍知之甚少。本研究调查了慢性阻塞性肺疾病急性加重(AECOPD)期间肠道和肺部微生物的动态变化。对 15 名 AECOPD 患者的 90 份粪便和痰液样本进行了为期 16S 核糖体 DNA 的纵向肠道和肺部微生物组调查,这些样本在三次就诊时被定义为加重期、七天稳定期。本分析显示了一个动态的肠道-肺部微生物群,其中的变化似乎与提示特定加重表型的加重事件有关。抗生素和类固醇治疗似乎对肠道-肺部微生物组有不同的影响,微生物组与疾病进展有关,但与严重程度无关。微生物组的丰度和多样性受到疾病进展和治疗的强烈影响。使用非培养方法影响 AECOPD 患者的肠道和肺部微生物组可能是理解肠道和肺部相互作用的关键,突出了其作为生物标志物的潜力,并可能成为未来呼吸治疗的靶点。